Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology reports a loss for the six months ended June 30, 2024, despite an increase in revenue compared to the same period in 2023. The company has been actively progressing its drug pipeline, achieving milestones such as marketing approval for KN035 in Macau and publishing positive clinical trial results for its cancer treatments. Alphamab is making strategic partnerships to expand the reach of its oncology drug KN035, including a licensing agreement with Glenmark for multiple regions.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
